enspryng
(Satralizumab)Genentech Inc.
Usage: ENSPRYNG is indicated for treating neuromyelitis optica spectrum disorder (NMOSD) in adult patients who test positive for anti-aquaporin-4 (AQP4) antibodies.
4 results
soliris
(ECULIZUMAB)Alexion Pharmaceuticals Inc.Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.ultomiris
(ravulizumab)Alexion Pharmaceuticals Inc.Usage: ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.uplizna
(Inebilizumab)Horizon Therapeutics USA, Inc.Usage: UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with anti-aquaporin-4 (AQP4) antibody positivity and for immunoglobulin G4-related disease (IgG4-RD) in adults.